Substandard and counterfeit medicines: A systematic review of the literature

BMJ Open

Volumn 3, Issue 8, 2013, Pages

  Almuzaini, Tariq ^a   Choonara, Imti ^a   Sammons, Helen ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; COUNTERFEIT DRUG;

ARTICLE; CHECKLIST; CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; CLINICAL PROTOCOL; DRUG INDUSTRY; DRUG QUALITY; EMBASE; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN; INCOME; LOWEST INCOME GROUP; MEDLINE; MULTICENTER STUDY (TOPIC); PRACTICE GUIDELINE; PREVALENCE; PURCHASING; QUALITY CONTROL; SAMPLE SIZE; STANDARD; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION;

EID: 84885345626     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-002923     Document Type: Article

References (41)

1. Caudron JM, Ford N, Henkens M., et al Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health 2008;13:1062-72.
2. Newton PN, Green MD, Fernández FM. Impact of poor-quality medicines in the 'developing' world. Trends Pharmacol Sci 2010;31:99-101.
3. Mackey TK, Liang BA The global counterfeit drug trade: patient safety and public health risks. J Pharm Sci 2011;100:4571-9.
4. Liang B. Fade to black: importation and counterfeit drugs. Am J Law Med 2006;32:279-323. (Pubitemid 44313674)
5. European Commission. Report on EU customs enforcement of intellectual property rights: results at the EU border. 2011. http://ec.europa.eu/taxation- customs/resources/documents/customs/customs-controls/counterfeit-piracy/ statistics/2012-ipr-statistics-en.pdf (accessed 23 May 2013).
6. Attaran A, Barry D, Basheer S., et al How to achieve international action on falsified and substandard medicines. BMJ 2012;345:e7381.
7. WHO. Counterfeit drugs guidelines for the development of measures to combat counterfeit drugs. WHO/EDM/QSM/99.1. Geneva: WHO, 1999. http://whqlibdoc.who.int/hq/1999/WHO-EDM-QSM-99.1.pdf (accessed 10 Apr 2011).
8. WHO. What are substandard medicines? http://www.who.int/medicines/ services/counterfeit/faqs/06/en/ (accessed 23 May 2013).
9. PSI-Inc. (Pharmaceutical Security Institute). Counterfeit situation. http://www.psi-inc.org/incidentTrends.cfm (accessed 23 May 2013).
10. The Institute of Medicine (IOM). Countering the Problem of Falsified and Substandard Drugs report. 2013. http://www.iom.edu/Reports/2013/Countering-the- Problem-of-Falsified-and-Substandard-Drugs.aspx (accessed 23 May 2013).
11. Moher D, Liberati A, Tetzlaff J., et al Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
12. World Bank. How we Classify Countries. http://data.worldbank.org/about/ country-classifications (accessed 25 May 2013).
13. Newton PN, Amin AA, Bird C, et al. The primacy of public health considerations in defining poor quality medicines. PLoS Med 2011;8: e1001139.
14. Newton PN, Lee SJ, Goodman C, et al. Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med 2009;6:e1000052.
15. Lon CT, Tsuyuoka R, Phanouvong S., et al Counterfeit and substandard antimalarial drugs in Cambodia. Trans R Soc Trop Med Hyg 2006; 100:1019-24. (Pubitemid 44334726)
16. Kaur H, Goodman C, Thompson E., et al A nationwide survey of the quality of antimalarials in retail outlets in Tanzania. PLoS ONE 2008;3:e3403.
17. Syhakhang L, Lundborg CS, Lindgren B, et al The quality of drugs in private pharmacies in Lao PDR: a repeat study in 1997 and 1999. Pharm World Sci 2004;26:333-8.
18. Ogwal-Okeng J., Owino E, Obua C. Chloroquine in the Ugandan market fails quality test: a pharmacovigilance study. Afr Health Sci 2003;3:2-6.
19. Onwujekwe O, Kaur H, Dike N., et al Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria. Malar J 2009;8:22.
20. Hadi U, van den Broek P, Kolopaking E, et al. Cross-sectional study of availability and pharmaceutical quality of antibiotics requested with or without prescription (Over The Counter) in Surabaya, Indonesia. BMC Infect Dis 2010; 10:203.
21. Basco LK. Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. Am J Trop Med Hyg 2004;70:245-50. (Pubitemid 38366526)
22. Taylor RB, Shakoor O, Behrens R.H., et al Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 2001;357:1933-6. (Pubitemid 32568335)
23. Wondemagegnehu E. Counterfeit and substandard drugs in Myanmar and Vietnam. Geneva: World Health Organization, 1999. WHO/EDM/QSM/99.3. http://apps.who.int/medicinedocs/pdf/s2276e/s2276e.pdf (accessed 23 May 2013).
24. Maponga C, Ondari C. The quality of antimalarials. A study in selected African countries. Geneva: World Health Organization, 2003. WHO/EDM/PAR/2003.4. http://apps.who.int/medicinedocs/pdf/s4901e/s4901e.pdf (accessed 23 May 2013).
25. Shakoor O, Taylor RB, Behrens RH Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health 1997;2:839-45. (Pubitemid 27396011)
26. Sabartova J, Toumi A, Ondari C. Survey of the quality of selected antimalarial medicines circulating in six countries of sub-Saharan Africa. Geneva: World Health Organization, 2011. WHO/EMP/QSM/2011.1. http://www.who.int/medicines/publications/WHO-QAMSA-report.pdf (accessed 23 May 2013).
27. A collaborative study by the WHO and DQI. Survey of the quality of selected antimalarial medicines circulating in Madagascar, Senegal, and Uganda. November 2009. http://apps.who.int/medicinedocs/documents/s17069e/s17069e.pdf (accessed 23 May 2013).
28. Dondorp AM, Newton PN, Mayxay M, et al Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 2004;9:1241-6. (Pubitemid 40037159)
29. Sabartova J, Nathanson E, Polishchuk O. Survey of the quality of anti-tuberculosis medicines circulating in selected newly independent states of the former Soviet Union. Geneva: World Health Organization, 2011. WHO/EMP/QSM/2011.2. http://apps.who.int/medicinedocs/documents/s19053en/ s19053en.pdf (accessed 23 May 2013).
30. Dorlo TPC, Ravinetto RM, Beijnen J.H., et al Commentary: substandard medicines are the priority for neglected tropical diseases. BMJ 2012;345:e7518.
31. Terlouw DJ, Nahlen BL, Courval J.M., et al Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing. Antimicrob Agents Chemother 2003;47:2929-32. (Pubitemid 37040270)
32. Barnes KI, Watkins WM, White NJ Antimalarial dosing regimens and drug resistance. Trends Parasitol 2008;24:127-34.
33. WHO. Guidelines for the treatment of malaria. 2nd edn. 2010. http://whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf (accessed 25 May 2013).
34. Abdoulaye I, Chastanier H, Azondekon A. Survey on the illicit drug market in Cotonou, Benin in March 2003. Med Trop (Mars) 2006;66:573-6. (Pubitemid 350246744)
35. Wertheimer AI, Norris J. Safeguarding against substandard/counterfeit drugs: mitigating a macroeconomic pandemic. Res Social Adm Pharm 2009;5:4-16.
36. Health Action International (HAI). Medicine pricing matters. Taxing essential medicines-a sick tax that hinders access to treatment. December 2009. http://www.haiweb.org/medicineprices/29012010/MPM-6.pdf (accessed 11 June 2013).
37. Interpol. Pharmaceutical crime. 2012. COM/FS/2012-01/DCO-04. http://www.interpol.int/content/download/3902/37957/version/17/file/ Factsheets-EN-jun2012-DCO04.pdf (accessed 24 May 2013).
38. WCO. International operation combats the online supply of counterfeit and illegal medicines. November 2009. http://www.wcoomd.org/en/media/newsroom/2009/ november/international-operation-combats-the-online-supply-of-counterfeit-and- illegal-medicines.aspx (accessed 24 May 2013).
39. UNDOC. UN drugs and crime office, World Customs Organization make a dent in counterfeit goods and drug shipments. 2012. http://www.unodc.org/unodc/en/ press/releases/2012/June/un-drugs-and-crime-office-world-customs-organization- make-a-dent-on-counterfeit-goods-and-drug-shipments.html (accessed 24 May 2013).
40. WHO. Substandard/spurious/falsely-labelled/falsified/counterfeit medical products: report of the Working Group of Member States. 2012. http://apps.who.int/gb/ebwha/pdf-files/WHA65/A65-23-en.pdf (accessed 23 May 2013).
41. WHO. New global mechanism to combat Substandard/Spurious/Falselylabelled/ Falsified/Counterfeit medical products. 2012. http://www.who.int/medicines/news/ TRA-SE-EMP.pdf (accessed 23 May 2013).